MedTrace Logo

Ranibizumab for Myopic Neovascularization

NCT01246089 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-01-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).

Conditions

  • Myopic Choroidal Neovascularization

Interventions

DRUG

ranibizumab injection

Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)

Sponsors & Collaborators

  • Instituto de Olhos de Goiania

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2014-10-31
Completion
2014-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01246089 on ClinicalTrials.gov